Sepideh Abbaszadeh, Karim Parastouei, Hossein Afshari, Leila Rostami, Hamdollah Mahmoudi, Mohammad E Ghamarchehreh, Mojtaba Sepandi, Mohammad Samadi, Ghader Ghanizadeh, Seyed Moayed Alavian
a Health Research Center.
e Baqiyatallah University of Medical Sciences, Tehran, IRAN; Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences , Tehran , IRAN.
J Am Coll Nutr. 2016 Aug;35(6):500-505. doi: 10.1080/07315724.2015.1031355. Epub 2015 Oct 2.
Nonalcoholic fatty liver disease (NAFLD) is a condition defined by exceeding triglycerides accumulation in the liver. The condition can develop into fibrosis, cirrhosis, and hepatocellular carcinoma. Considering the ever-increasing prevalence of NAFLD, the aim of the present study was to investigate the effects of probiotic supplementation on glycemic and inflammatory indices in patients with NAFLD.
This randomized clinical trial was conducted on 42 patients with NAFLD who had been referred to a gastroenterology clinic. Subjects in the intervention and control groups consumed 2 capsules/day probiotic or placebo, respectively, for 8 weeks. Fasting blood sugar (FBS), insulin, insulin resistance, tumor necrosis factor alpha (TNF-α), and interleukin 6 (IL-6) were measured at baseline and at the end of the study.
Means of FBS, insulin, insulin resistance, and IL-6 were significantly different between groups after intervention (p < 0.05), whereas TNF-α was not significantly modified (p > 0.05). In the probiotic group, insulin, insulin resistance, TNF-α, and IL-6 decreased significantly at the end of the study compared to the beginning of study.
Considering the effects of probiotic supplementation on the reduction of glycemic and inflammatory indices in patients with NAFLD, consumption of probiotics is recommended as a complementary therapy in these patients.
非酒精性脂肪性肝病(NAFLD)是一种因肝脏中甘油三酯蓄积过多而定义的病症。该病症可发展为肝纤维化、肝硬化和肝细胞癌。鉴于NAFLD的患病率不断上升,本研究的目的是调查补充益生菌对NAFLD患者血糖和炎症指标的影响。
本随机临床试验对42名转诊至胃肠病诊所的NAFLD患者进行。干预组和对照组的受试者分别每天服用2粒益生菌胶囊或安慰剂,持续8周。在基线和研究结束时测量空腹血糖(FBS)、胰岛素、胰岛素抵抗、肿瘤坏死因子α(TNF-α)和白细胞介素6(IL-6)。
干预后两组间FBS、胰岛素、胰岛素抵抗和IL-6的均值有显著差异(p < 0.05),而TNF-α无显著变化(p > 0.05)。在益生菌组中,与研究开始时相比,研究结束时胰岛素、胰岛素抵抗、TNF-α和IL-6显著降低。
考虑到补充益生菌对降低NAFLD患者血糖和炎症指标的作用,建议将益生菌作为这些患者的辅助治疗方法。